+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Oncology NGS Market Research Report by Technology, Product & Service, Application, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

  • PDF Icon

    Report

  • 143 Pages
  • January 2023
  • Region: United States
  • 360iResearch™
  • ID: 5722816
The United States Oncology NGS Market is projected to grow with a significant CAGR in the forecast period. Economic development and substantial infrastructure development have constituted regional revenue generation. Further, the patterns associated with domestic production, import and export, and consumption have helped market participants to analyze and capitalize on potential opportunities. Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the United States Oncology NGS Market.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the United States Oncology NGS Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the United States Oncology NGS Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The United States Oncology NGS Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the United States Oncology NGS Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the United States Oncology NGS Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Technology, the market is studied across Amplicon-based, Hybridization-based, Targeted & Gene Panel Sequencing, Whole Exome Sequencing, and Whole Genome Sequencing.
  • Based on Product & Service, the market is studied across Platforms & Related Products and Services. The Platforms & Related Products is is further studied across Consumables, Panels, and Platforms. The Services is is further studied across By Workflow, NGS Data Analysis, NGS Pre-Sequencing, NGS Primary Data Analysis, NGS Secondary Data Analysis, NGS Sequencing, and NGS Tertiary Data Analysis.
  • Based on Application, the market is studied across Academic & Clinical Research, Hospitals & Clinics, and Pharma & Biotech Entities.
  • Based on State, the market is studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the United States Oncology NGS Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The United States Oncology NGS Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The United States Oncology NGS Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The United States Oncology NGS Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Oncology NGS Market, including 4basecare Onco Solutions Private Limited, BGI Group, Caris Life Sciences, Eurofins Scientific SE, Foundation Medicine, Inc., Genotypic Technology Pvt. Ltd., Hologic, Inc., MedGenome, Myriad Genetics, Inc., PerkinElmer Inc., Premas Life Sciences, Sayre Therapeutics Pvt Ltd., SciGenom Labs Pvt. Ltd., Tecan Trading AG, Vela Diagnostics Holding Pte Ltd., and Xcelris Labs Ltd..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Oncology NGS Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Oncology NGS Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Oncology NGS Market?
4. What is the competitive strategic window for opportunities in the United States Oncology NGS Market?
5. What are the technology trends and regulatory frameworks in the United States Oncology NGS Market?
6. What is the market share of the leading vendors in the United States Oncology NGS Market?
7. What modes and strategic moves are considered suitable for entering the United States Oncology NGS Market?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing burden of cancers in the U.S.
5.1.1.2. Government investments to digitize healthcare sector
5.1.2. Restraints
5.1.2.1. Complexity associated with technology deployment
5.1.3. Opportunities
5.1.3.1. Technological advances in oncology NGS
5.1.4. Challenges
5.1.4.1. Vulnerability to cyberattacks and breaches
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Oncology NGS Market, by Technology
6.1. Introduction
6.2. Amplicon-based
6.3. Hybridization-based
6.4. Targeted & Gene Panel Sequencing
6.5. Whole Exome Sequencing
6.6. Whole Genome Sequencing

7. Oncology NGS Market, by Product & Service
7.1. Introduction
7.2. Platforms & Related Products
7.3.1. Consumables
7.3.2. Panels
7.3.3. Platforms
7.3. Services
7.4.1. By Workflow
7.4.2. NGS Data Analysis
7.4.3. NGS Pre-Sequencing
7.4.4. NGS Primary Data Analysis
7.4.5. NGS Secondary Data Analysis
7.4.6. NGS Sequencing
7.4.7. NGS Tertiary Data Analysis

8. Oncology NGS Market, by Application
8.1. Introduction
8.2. Academic & Clinical Research
8.3. Hospitals & Clinics
8.4. Pharma & Biotech Entities

9. California Oncology NGS Market
9.1. Introduction

10. Florida Oncology NGS Market
10.1. Introduction

11. Illinois Oncology NGS Market
11.1. Introduction

12. New York Oncology NGS Market
12.1. Introduction

13. Ohio Oncology NGS Market
13.1. Introduction

14. Pennsylvania Oncology NGS Market
14.1. Introduction

15. Texas Oncology NGS Market
15.1. Introduction

16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis, By Key Player
16.3. Market Share Analysis, By Key Player
16.4. Product Portfolio Analysis, By Key Player
16.5. Competitive Scenario
16.5.1. Merger & Acquisition
16.5.2. Agreement, Collaboration, & Partnership
16.5.3. New Product Launch & Enhancement
16.5.4. Investment & Funding
16.5.5. Award, Recognition, & Expansion

17. Company Usability Profiles
17.1. 4basecare Onco Solutions Private Limited
17.2. BGI Group
17.3. Caris Life Sciences
17.4. Eurofins Scientific SE
17.5. Foundation Medicine, Inc.
17.6. Genotypic Technology Pvt. Ltd.
17.7. Hologic, Inc.
17.8. MedGenome
17.9. Myriad Genetics, Inc.
17.10. PerkinElmer Inc.
17.11. Premas Life Sciences
17.12. Sayre Therapeutics Pvt Ltd.
17.13. SciGenom Labs Pvt. Ltd.
17.14. Tecan Trading AG
17.15. Vela Diagnostics Holding Pte Ltd.
17.16. Xcelris Labs Ltd.

18. Appendix
18.1. Discussion Guide
18.2. License & Pricing

List of Figures
FIGURE 1. UNITED STATES ONCOLOGY NGS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES ONCOLOGY NGS MARKET SIZE, 2022 VS 2030
FIGURE 3. UNITED STATES ONCOLOGY NGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 5. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. UNITED STATES ONCOLOGY NGS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 7. UNITED STATES ONCOLOGY NGS MARKET DYNAMICS
FIGURE 8. UNITED STATES ONCOLOGY NGS MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 9. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)
FIGURE 10. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. UNITED STATES ONCOLOGY NGS MARKET COMPETITIVE STRATEGIC WINDOW, BY TECHNOLOGY, 2030
FIGURE 12. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY AMPLICON-BASED, 2018-2030 (USD MILLION)
FIGURE 13. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY HYBRIDIZATION-BASED, 2018-2030 (USD MILLION)
FIGURE 14. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY TARGETED & GENE PANEL SEQUENCING, 2018-2030 (USD MILLION)
FIGURE 15. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY WHOLE EXOME SEQUENCING, 2018-2030 (USD MILLION)
FIGURE 16. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY WHOLE GENOME SEQUENCING, 2018-2030 (USD MILLION)
FIGURE 17. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY PRODUCT & SERVICE, 2022 VS 2030 (%)
FIGURE 18. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY PRODUCT & SERVICE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ONCOLOGY NGS MARKET COMPETITIVE STRATEGIC WINDOW, BY PRODUCT & SERVICE, 2030
FIGURE 20. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY PLATFORMS & RELATED PRODUCTS, 2018-2030 (USD MILLION)
FIGURE 21. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
FIGURE 22. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY PANELS, 2018-2030 (USD MILLION)
FIGURE 23. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2030 (USD MILLION)
FIGURE 24. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
FIGURE 25. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY BY WORKFLOW, 2018-2030 (USD MILLION)
FIGURE 26. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY NGS DATA ANALYSIS, 2018-2030 (USD MILLION)
FIGURE 27. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY NGS PRE-SEQUENCING, 2018-2030 (USD MILLION)
FIGURE 28. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY NGS PRIMARY DATA ANALYSIS, 2018-2030 (USD MILLION)
FIGURE 29. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY NGS SECONDARY DATA ANALYSIS, 2018-2030 (USD MILLION)
FIGURE 30. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY NGS SEQUENCING, 2018-2030 (USD MILLION)
FIGURE 31. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY NGS TERTIARY DATA ANALYSIS, 2018-2030 (USD MILLION)
FIGURE 32. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
FIGURE 33. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 34. UNITED STATES ONCOLOGY NGS MARKET COMPETITIVE STRATEGIC WINDOW, BY APPLICATION, 2030
FIGURE 35. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY ACADEMIC & CLINICAL RESEARCH, 2018-2030 (USD MILLION)
FIGURE 36. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
FIGURE 37. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY PHARMA & BIOTECH ENTITIES, 2018-2030 (USD MILLION)
FIGURE 38. CALIFORNIA ONCOLOGY NGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 39. FLORIDA ONCOLOGY NGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 40. ILLINOIS ONCOLOGY NGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 41. NEW YORK ONCOLOGY NGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 42. OHIO ONCOLOGY NGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 43. PENNSYLVANIA ONCOLOGY NGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 44. TEXAS ONCOLOGY NGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 45. UNITED STATES ONCOLOGY NGS MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 46. UNITED STATES ONCOLOGY NGS MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 47. UNITED STATES ONCOLOGY NGS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022


List of Tables
TABLE 1. UNITED STATES ONCOLOGY NGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. UNITED STATES ONCOLOGY NGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 5. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 6. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY AMPLICON-BASED, 2018-2030 (USD MILLION)
TABLE 7. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY AMPLICON-BASED, BY STATE, 2018-2030 (USD MILLION)
TABLE 8. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY HYBRIDIZATION-BASED, 2018-2030 (USD MILLION)
TABLE 9. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY HYBRIDIZATION-BASED, BY STATE, 2018-2030 (USD MILLION)
TABLE 10. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY TARGETED & GENE PANEL SEQUENCING, 2018-2030 (USD MILLION)
TABLE 11. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY TARGETED & GENE PANEL SEQUENCING, BY STATE, 2018-2030 (USD MILLION)
TABLE 12. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY WHOLE EXOME SEQUENCING, 2018-2030 (USD MILLION)
TABLE 13. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY STATE, 2018-2030 (USD MILLION)
TABLE 14. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY WHOLE GENOME SEQUENCING, 2018-2030 (USD MILLION)
TABLE 15. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY STATE, 2018-2030 (USD MILLION)
TABLE 16. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 17. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY PLATFORMS & RELATED PRODUCTS, 2018-2030 (USD MILLION)
TABLE 18. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY PLATFORMS & RELATED PRODUCTS, BY STATE, 2018-2030 (USD MILLION)
TABLE 19. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 20. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY CONSUMABLES, BY STATE, 2018-2030 (USD MILLION)
TABLE 21. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY PANELS, 2018-2030 (USD MILLION)
TABLE 22. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY PANELS, BY STATE, 2018-2030 (USD MILLION)
TABLE 23. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, BY STATE, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY SERVICES, BY STATE, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY BY WORKFLOW, BY STATE, 2018-2030 (USD MILLION)
TABLE 29. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY NGS DATA ANALYSIS, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY NGS DATA ANALYSIS, BY STATE, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY NGS PRE-SEQUENCING, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY NGS PRE-SEQUENCING, BY STATE, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY NGS PRIMARY DATA ANALYSIS, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY NGS PRIMARY DATA ANALYSIS, BY STATE, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY NGS SECONDARY DATA ANALYSIS, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY NGS SECONDARY DATA ANALYSIS, BY STATE, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY NGS SEQUENCING, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY NGS SEQUENCING, BY STATE, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY NGS TERTIARY DATA ANALYSIS, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY NGS TERTIARY DATA ANALYSIS, BY STATE, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY ACADEMIC & CLINICAL RESEARCH, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY ACADEMIC & CLINICAL RESEARCH, BY STATE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CLINICS, BY STATE, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY PHARMA & BIOTECH ENTITIES, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES ONCOLOGY NGS MARKET SIZE, BY PHARMA & BIOTECH ENTITIES, BY STATE, 2018-2030 (USD MILLION)
TABLE 48. CALIFORNIA ONCOLOGY NGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 49. CALIFORNIA ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 50. CALIFORNIA ONCOLOGY NGS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 51. CALIFORNIA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. FLORIDA ONCOLOGY NGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 53. FLORIDA ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 54. FLORIDA ONCOLOGY NGS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 55. FLORIDA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. ILLINOIS ONCOLOGY NGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 57. ILLINOIS ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 58. ILLINOIS ONCOLOGY NGS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 59. ILLINOIS ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. NEW YORK ONCOLOGY NGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 61. NEW YORK ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 62. NEW YORK ONCOLOGY NGS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 63. NEW YORK ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. OHIO ONCOLOGY NGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 65. OHIO ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 66. OHIO ONCOLOGY NGS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 67. OHIO ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. PENNSYLVANIA ONCOLOGY NGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 69. PENNSYLVANIA ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 70. PENNSYLVANIA ONCOLOGY NGS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 71. PENNSYLVANIA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 72. TEXAS ONCOLOGY NGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 73. TEXAS ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 74. TEXAS ONCOLOGY NGS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 75. TEXAS ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES ONCOLOGY NGS MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 77. UNITED STATES ONCOLOGY NGS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 78. UNITED STATES ONCOLOGY NGS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 79. UNITED STATES ONCOLOGY NGS MARKET RANKING, BY KEY PLAYER, 2022
TABLE 80. UNITED STATES ONCOLOGY NGS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 81. UNITED STATES ONCOLOGY NGS MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 82. UNITED STATES ONCOLOGY NGS MARKET MERGER & ACQUISITION
TABLE 83. UNITED STATES ONCOLOGY NGS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 84. UNITED STATES ONCOLOGY NGS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 85. UNITED STATES ONCOLOGY NGS MARKET INVESTMENT & FUNDING
TABLE 86. UNITED STATES ONCOLOGY NGS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 87. UNITED STATES ONCOLOGY NGS MARKET: LICENSE & PRICING

Companies Mentioned

  • 4basecare Onco Solutions Private Limited
  • BGI Group
  • Caris Life Sciences
  • Eurofins Scientific SE
  • Foundation Medicine, Inc.
  • Genotypic Technology Pvt. Ltd.
  • Hologic, Inc.
  • MedGenome
  • Myriad Genetics, Inc.
  • PerkinElmer Inc.
  • Premas Life Sciences
  • Sayre Therapeutics Pvt Ltd.
  • SciGenom Labs Pvt. Ltd.
  • Tecan Trading AG
  • Vela Diagnostics Holding Pte Ltd.
  • Xcelris Labs Ltd.

Methodology

Loading
LOADING...